<DOC>
	<DOCNO>NCT01112085</DOCNO>
	<brief_summary>The objective study investigate drug ranibizumab administrate microdose injection eye safe effective treat diabetic macular edema .</brief_summary>
	<brief_title>MIcrodoses raNIbizumab Diabetic MAcular Edema ( MINIMA-2 )</brief_title>
	<detailed_description>The MINIMA-2 Study multi-center clinical trial initiate order investigate effect microdoses ranibizumab diabetic macular edema . The duration study 13 month . Patients diabetic macular edema randomize 2 different group . Consented subject receive monthly injection 6-month treatment period , 6 month follow-up treatment period . Several eye examination procedure perform evaluate response treatment . These include best correct visual acuity testing ( ETDRS ) , contrast sensitivity testing , ophthalmic examination , fluorescein angiography ( FA ) macular thickness measurement base optical coherence tomography ( OCT ) . Serum chemistry , hematology glycosylated hemoglobin HbA1c testing , urinalysis pregnancy test perform screen visit ( Days -14 0 ) two time study . Approximately 72 patient baseline central foveal thickness OCT least 270 include . The BCVA must worst 20/40 good equal 20/320 due diabetic macular edema .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Male female subject , 18 year age old Subjects diagnosis diabetes mellitus ( Type I II ) Signed informed consent Patient must able comply study assessment Clinical sings angiographic evidence diabetic macular edema Central foveal thickness least 270 assessed OCT Best correct visual acuity 20/40 20/320 ( ETDRS chart ) study eye Patients fulfill inclusion criterion Use intraocular periocular drug injection previous 3 month Macular panretinal photocoagulation within 3 month study entry study eye High myopia ( 6D ) Any ocular disorder study eye may confound interpretation study result include patient choroidal neovascularization , macular hole , retinal detachment , epiretinal membrane , ischemic maculopathy retinal vascular disease vascular occlusive disease . Vitreomacular traction Subretinal fibrosis Uncontrolled advance glaucoma Active ocular inflammation history active intraocular inflammation 6 month prior enrollment study Any ophthalmic surgery perform within 3 month prior study entry study eye Previous par plana vitrectomy study eye History ocular trauma type study eye Subjects medium opacity abnormality would preclude observation retina study eye , per investigator 's judgement History fluorescein allergy Known hypersensitivity ranibizumab History stroke Myocardial infraction within 6 month Pregnancy , lactation woman adequate contraception Participation another simultaneous medical investigation trial Any condition , opinion investigator , would produce significant hazard jeopardize safety patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Diabetic macular edema</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>